Bruno Silva-Santos is Full Professor and Director of Immuno-Oncology at the Faculty of Medicine of the University of Lisbon, and Group Leader at the Gulbenkian Institute for Molecular Medicine in Lisbon, Portugal. He is the current President of the Portuguese Society for Immunology. His research has been funded by the European Research Council (2010 and 2015) and the la Caixa Foundation (2020 and 2024), among others, and resulted in over 120 papers in top peer-reviewed journals. His patented immunotherapy technology, “Delta One T (DOT) cells”, has been acquired by Takeda Pharmaceutical (2022) and is currently under clinical testing in leukemia patients the USA (NCT05886491).